Non-proinflammatory and responsive nanoplatforms for targeted treatment of atherosclerosis
- PMID: 28778000
- DOI: 10.1016/j.biomaterials.2017.07.035
Non-proinflammatory and responsive nanoplatforms for targeted treatment of atherosclerosis
Abstract
Atherosclerosis is the leading cause of many fatal cardiovascular and cerebrovascular diseases. Whereas nanomedicines are promising for targeted therapy of atherosclerosis, great challenges remain in development of effective, safe, and translational nanotherapies for its treatment. Herein we hypothesize that non-proinflammatory nanomaterials sensitive to low pH or high reactive oxygen species (ROS) may serve as effective platforms for triggerable delivery of anti-atherosclerotic therapeutics in cellular and tissue microenvironments of inflammation. To demonstrate this hypothesis, an acid-labile material of acetalated β-cyclodextrin (β-CD) (Ac-bCD) and a ROS-sensitive β-CD material (Ox-bCD) were separately synthesized by chemical modification of β-CD, which were formed into responsive nanoparticles (NPs). Ac-bCD NP was rapidly hydrolyzed in mildly acidic buffers, while hydrolysis of Ox-bCD NP was selectively accelerated by H2O2. Using an anti-atherosclerotic drug rapamycin (RAP), we found stimuli-responsive release of therapeutic molecules from Ac-bCD and Ox-bCD nanotherapies. Compared with non-responsive poly(lactide-co-glycolide) (PLGA)-based NP, Ac-bCD and Ox-bCD NPs showed negligible inflammatory responses in vitro and in vivo. By endocytosis in cells and intracellularly releasing cargo molecules in macrophages, responsive nanotherapies effectively inhibited macrophage proliferation and suppressed foam cell formation. After intraperitoneal (i.p.) delivery in apolipoprotein E-deficient (ApoE-/-) mice, fluorescence imaging showed accumulation of NPs in atherosclerotic plaques. Flow cytometry analysis indicated that the lymphatic translocation mediated by neutrophils and monocytes/macrophages may contribute to atherosclerosis targeting of i.p. administered NPs, in addition to targeting via the leaky blood vessels. Correspondingly, i.p. treatment with different nanotherapies afforded desirable efficacies. Particularly, both pH and ROS-responsive nanomedicines more remarkably delayed progression of atherosclerosis and significantly enhanced stability of atheromatous lesions, in comparison to non-responsive PLGA nanotherapy. Furthermore, responsive nanovehicles displayed good safety performance after long-term administration in mice. Consequently, for the first time our findings demonstrated the therapeutic advantages of nanomedicines responsive to mildly acidic or abnormally high ROS microenvironments for the treatment of atherosclerosis.
Keywords: Atherosclerosis; Cyclodextrin materials; Inflammation; Reactive oxygen species; Responsive nanotherapy; Targeting.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Similar articles
-
Nanoparticles responsive to the inflammatory microenvironment for targeted treatment of arterial restenosis.Biomaterials. 2016 Oct;105:167-184. doi: 10.1016/j.biomaterials.2016.08.003. Epub 2016 Aug 4. Biomaterials. 2016. PMID: 27522252
-
Sustained delivery by a cyclodextrin material-based nanocarrier potentiates antiatherosclerotic activity of rapamycin via selectively inhibiting mTORC1 in mice.J Control Release. 2016 Aug 10;235:48-62. doi: 10.1016/j.jconrel.2016.05.049. Epub 2016 May 25. J Control Release. 2016. PMID: 27235978
-
A pH/ROS dual-responsive and targeting nanotherapy for vascular inflammatory diseases.Biomaterials. 2020 Feb;230:119605. doi: 10.1016/j.biomaterials.2019.119605. Epub 2019 Nov 8. Biomaterials. 2020. PMID: 31740099
-
Current targeting strategies and advanced nanoplatforms for atherosclerosis therapy.J Drug Target. 2024 Dec;32(2):128-147. doi: 10.1080/1061186X.2023.2300694. Epub 2024 Feb 1. J Drug Target. 2024. PMID: 38217526 Review.
-
High-density lipoprotein-based nanoplatforms for macrophage-targeted diagnosis and therapy of atherosclerosis.Int J Biol Macromol. 2025 May;306(Pt 3):140826. doi: 10.1016/j.ijbiomac.2025.140826. Epub 2025 Feb 24. Int J Biol Macromol. 2025. PMID: 40010459 Review.
Cited by
-
Antioxidant Nanotherapies for the Treatment of Inflammatory Diseases.Front Bioeng Biotechnol. 2020 Mar 18;8:200. doi: 10.3389/fbioe.2020.00200. eCollection 2020. Front Bioeng Biotechnol. 2020. PMID: 32258013 Free PMC article. Review.
-
Revolutionizing healthcare: the transformative potential of nanotechnology in medicine.Front Drug Deliv. 2025 May 30;5:1556426. doi: 10.3389/fddev.2025.1556426. eCollection 2025. Front Drug Deliv. 2025. PMID: 40837709 Free PMC article. Review.
-
Pathologically triggered in situ aggregation of nanoparticles for inflammation-targeting amplification and therapeutic potentiation.Acta Pharm Sin B. 2023 Jan;13(1):390-409. doi: 10.1016/j.apsb.2022.07.013. Epub 2022 Jul 20. Acta Pharm Sin B. 2023. PMID: 36815041 Free PMC article.
-
Folic acid-modified ROS-responsive nanoparticles encapsulating luteolin for targeted breast cancer treatment.Drug Deliv. 2021 Dec;28(1):1695-1708. doi: 10.1080/10717544.2021.1963351. Drug Deliv. 2021. PMID: 34402706 Free PMC article.
-
ROS-responsive & scavenging NO nanomedicine for vascular diseases treatment by inhibiting endoplasmic reticulum stress and improving NO bioavailability.Bioact Mater. 2024 Mar 22;37:239-252. doi: 10.1016/j.bioactmat.2024.03.010. eCollection 2024 Jul. Bioact Mater. 2024. PMID: 38549770 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous